Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

• US 8,349,319 B2
• Filed: 08/28/2010
• Issued: 01/08/2013
• Est. Priority Date: 08/28/2009
• Status: Active Grant

• Current Assignee: Icahn School of Medicine at Mount Sinai
• Original Assignee: Genzyme Corporation (Sanofi ), Mount Sinai School of Medicine (Sinai Health System)
• Inventors: Schuchman, Edward H., Desnick, Robert J., Cox, Gerald F., Andrews, Laura P., Murray, James M.
• Primary Examiner(s): GITOMER, RALPH J
• Application Number:
  US12/870,790
• Publication Number:
  US 20110052559A1
• Time in Patent Office: 864 Days
• Field of Search: 424/94.6, 424/94.61
• US Class Current: 424/94.6
• CPC Class Codes: A61K 38/465 acting on ester bonds (3.1), e.g. lipases, ribonucleases
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: C12Y 301/04012 Sphingomyelin phosphodiesterase (3.1.4.12)

Abstract

The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.

Claims

1. A method for treating a human subject having an acid sphingomyelinase deficiency, comprising administering recombinant human acid sphingomyelinase (rhASM) in an escalating dose regimen at the following sequential doses:

(a) 0.1 mg/kg,

(b) 0.3 mg/kg, and

(c) 0.6 mg/kg;

wherein each dose of rhASM is administered at two week intervals, wherein each dose is administered at least once before elevating the dose to the next level, and wherein the subject is monitored for toxic side effects before elevating the dose to the next level.

2. The method of claim 1 further comprising a maintenance dose regimen comprising administering a dose equal to or less than the highest dose tolerated by the subject as the maintenance dose for the subject.

3. The method of claim 1 further comprising the following sequential dose:

(d) 1 mg/kg.

4. The method of claim 3 further comprising the following sequential dose:

(e) 2 mg/kg.

5. The method of claim 4 further comprising the following sequential dose:

(f) 3 mg/kg.

6. The method of claim 3, in which the further sequential dose of (d) is administered one, two, three or four weeks after the previous dose.

7. The method of claim 3, in which the further sequential dose of (d) is administered one week after the previous dose.

8. The method of claim 3, in which the further sequential dose of (d) is administered two weeks after the previous dose.

9. The method of claim 2 in which the highest dose tolerated is administered to the human subject as the maintenance dose.

10. The method of claim 2 in which the maintenance dose is a therapeutically effective dose less than the highest dose tolerated.

11. The method of claim 2 which further comprises monitoring the subject during the maintenance regimen for one or more adverse side effects as indicated by elevated bilirubin or a related adverse event;

and adjusting the maintenance dose.

12. The method of claim 2 in which the maintenance dose is administered to the subject every two to four weeks.

13. The method of claim 1 or 2 in which the doses are administered intravenously.

14. The method of claim 1 or 2 in which the doses are administered intradermally, subcutaneously or intramuscularly.

15. The method of claim 1 or 2 in which the acid sphingomyelinase deficiency is Niemann Pick Disease (NPD) type A.

16. The method of claim 1 or 2 in which the acid sphingomyelinase deficiency is NPD type B.

17. The method of claim 1 or 2 in which the human subject has a missense mutation in the gene encoding acid sphingomyelinase.

18. The method of claim 1 or 2 in which the mutation is L302P, H421Y or R496L.

19. The method of claim 1 or 2 in which the human subject has a mutation in the gene encoding acid sphingomyelinase and the mutation is Δ

R608.

20. The method of claim 1, wherein each dose of rhASM is administered at least two times before escalating the dose.

21. The method of claim 4, in which the further sequential dose of (e) is administered one, two, three or four weeks after the previous dose.

22. The method of claim 5, in which the further sequential dose of (f) is administered one, two, three or four weeks after the previous dose.

23. The method of claim 4, in which the further sequential dose of (e) is administered one week after the previous dose.

24. The method of claim 5, in which the further sequential dose of (f) is administered one week after the previous dose.

25. The method of claim 4, in which the further sequential dose of (e) is administered two weeks after the previous dose.

26. The method of claim 5, in which the further sequential dose of (f) is administered two weeks after the previous dose.